D-Pharm, an Israeli biopharma, signed a deal giving Jiangsu Nhwa Pharmaceutical Company (SHE: 2262) exclusive rights to develop its epilepsy treatment, DP-VPA, for China. Nhwa will be responsible for conducting the China clinical trials for the drug, which will be conducted following US FDA guidelines so D-Pharm can use the data to gain approval of DP-VPA in global markets. D-Pharm received $1 million up front, and it is due $1.4 million in milestone payments and 5% royalties on any sales over a specified threshold. More details....

Stock Symbol: (TASE: DPRM)     Share this with colleagues: